Helicobacter pylori Eradication Modulates Aberrant CpG Island Hypermethylation in Gastric Carcinogenesis

Korean J Gastroenterol. 2016 Nov 25;68(5):253-259. doi: 10.4166/kjg.2016.68.5.253.

Abstract

Background/aims: Helicobacter pylori infection induces aberrant DNA methylation in gastric mucosa. We evaluated the long-term effect of H. pylori eradication on promotor CpG island hypermethylation in gastric carcinogenesis.

Methods: H. pylori-positive patients with gastric adenoma or early gastric cancer who underwent endoscopic resection were enrolled. According to H. pylori eradication after endoscopic resection, the participants were randomly assigned to H. pylori eradication or non-eradication group. H. pylori-negative gastric mucosa from normal participants provided the normal control. CpG island hypermethylation of tumor-related genes (p16, CDH1, and RUNX-3) was evaluated by quantitative MethyLight assay in non-tumorous gastric mucosa. The gene methylation rate and median values of hypermethylation were compared after one year by H. pylori status.

Results: In H. pylori-positive patients, hypermethylation of p16 was found in 80.6%, of CDH1 in 80.6%, and of RUNX-3 in 48.4%. This is significantly higher than normal control (p16, 10%; CDH1, 44%; RUNX-3, 16%) (p<0.05). In the H. pylori eradication group, methylation rates of p16 and CDH1 decreased in 58.1% and 61.3% of the patients, and the median values of hypermethylation were significantly lower at one year compared with the non-eradication group. However, RUNX-3 hypermethylation did not differ significantly at one year after H. pylori eradication. The non-eradication group hypermethylation did not change after one year.

Conclusions: H. pylori infection was associated with promotor hypermethylation of genes in gastric carcinogenesis, and H. pylori eradication might reverse p16 and CDH1 hypermethylation.

Keywords: CDH1; Carcinogenesis; CpG hypermethylation; Helicobacter pylori; p16.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Antigens, CD
  • Cadherins / genetics
  • Case-Control Studies
  • Core Binding Factor Alpha 3 Subunit / genetics
  • CpG Islands
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics
  • DNA Methylation*
  • Down-Regulation / drug effects
  • Female
  • Gastric Mucosa / drug effects
  • Gastric Mucosa / metabolism
  • Helicobacter Infections / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Promoter Regions, Genetic
  • Stomach Neoplasms / etiology*

Substances

  • Anti-Bacterial Agents
  • Antigens, CD
  • CDH1 protein, human
  • Cadherins
  • Core Binding Factor Alpha 3 Subunit
  • Cyclin-Dependent Kinase Inhibitor p16
  • Runx3 protein, human